Install
Respiratory & Pulmonology
Asthma, COPD, sleep apnea, infections, and environmental lung risks.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
- Cardiology & Metabolic Health
- Oncology & Hematology
- Neurology & Neuroscience
- Orthopedics & Sports Medicine
- Gastroenterology & Hepatology
- Endocrinology & Hormones
- Nephrology & Urology
- Dermatology
- Rheumatology & Autoimmune
- OB‑GYN (Women’s Health)
- Pediatrics & Adolescent Health
- Geriatrics & Healthy Aging
- Ophthalmology & Vision
- ENT (Ear, Nose & Throat)
- Dentistry & Oral Health
Latest in Respiratory & Pulmonology
Be cautious of recurrent asthma attacks during seasonal changes.
3+ hour, 17+ min ago (269+ words) HNN - Understanding the true nature of asthma and consistently adhering to preventive treatment as prescribed by a doctor will help patients proactively control recurrent acute asthma attacks during seasonal changes. The risks of complacency Statistics from the Department of Endocrinology…...
Lighten Up: Laughter Is Good Medicine
13+ hour, 9+ min ago (277+ words) Posted October 12, 2026 | Reviewed by Abigail Fagan One of the most rewarding, enjoyable, and affordable pleasures in life is laughter. It relaxes our muscles, calms our mind, and is best enjoyed with others. Yet laughter apparently has additional benefits to both…...
Phase 3 Drug Trial Shows Lung Function Improvement for Patients with aPAP
2+ hour, 47+ min ago (586+ words) Research By: Bruce Trapnell, MS, MD Post Date: August 22, 2025 | Publish Date: August 20, 2025 APAP is a rare lung disease, with an estimated 10 people in a million living with the condition. The disease causes an abnormal build-up of surfactant in alveoli, the…...
Statins Effective in Treating Pulmonary Alveolar Proteinosis
2+ hour, 42+ min ago (142+ words) Research By: Bruce Trapnell, MD Post Date: July 1, 2019 | Publish Date: Aug. 7, 2018 Cholesterol-busting statins can effectively treat pulmonary alveolar proteinosis (PAP), a disease that causes air sacs in the lungs to clog with surfactant, according to new research led by Bruce…...
Student-driven initiative aims to improve lung health for firefighters, first responders
7+ hour, 6+ min ago (127+ words) LOS ANGELES — Firefighters face a risk of lung cancer at much higher rates than the average citizen because of exposure to toxic combustion, carcinogens such as asbestos, and repeated exposure to smoke. Bettina Lee, a 17-year-old Rancho Cucamonga senior, started…...
Air Pollution Linked to Millions of Deaths Worldwide as Cities Step Up Clean-Air Measures
2+ week, 6+ day ago (480+ words) Air pollution caused around 8 million deaths worldwide in 2023, according to the State of Global Air 2025 report, while the World Bank estimates that the health-related economic cost of pollution reaches $8.1 trillion annually, equivalent to nearly 6% of global GDP. Former World Health…...
Breckenridge announces launch of Tofacitinib Tablets, generic equivalent of Xeljanz® by Pfizer
3+ day, 5+ hour ago (179+ words) Jun 04, 2026, 10:17 ET BERKELEY HEIGHTS, N.J., June 4, 2026 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International that markets, distributes, and sells generic medicines in the United States, announced the launch of Tofacitinib Tablets, the generic equivalent of Xeljanz® by Pfizer, in the…...
Allergies worsen with warming climate
13+ hour, 59+ min ago (36+ words) FOX6 News Milwaukee Seasonal allergies can already last through late fall, but warming temperatures leads to more freeze-free days each year, giving plants more time to grow and release allergy-inducing pollen....
Bristol Myers' Phase 3 Trial Of Admilparant In Idiopathic Pulmonary Fibrosis Met Primary Endpoint
20+ hour, 22+ min ago (173+ words) Bristol Myers Squibb (BMY), a biopharmaceutical company, announced Monday the topline results from its pivotal Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis (IPF). Admilparant is a potential first-in-class, orally administered lysophosphatidic acid receptor 1 (LPA1) antagonist. The trial…...
Allergies or illness: How to tell the difference and when to seek treatment
6+ hour, 1+ min ago (293+ words) By Melissa Patrick, Kentucky Health News · October 12, 2026 Dr. Sarah Marks University of Kentucky Fall allergy season overlaps with cold and flu season in Kentucky, making this a challenging time of year. Knowing how allergies differ from viral respiratory infections, such…...